Oncology Clinical News

Celgene Settles Whistle-Blower Fraud Suit for $280 Million

(Bloomberg) July 25, 2017 - Celgene Corp. agreed to pay $280 million to resolve a whistle-blower’s claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. said.
Read full article.

Eisai Submits Simultaneous Applications In The United States And Europe For Lenvatinib In Hepatocellular Carcinoma

(Eisai) July 25, 2017 - Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC).
Read full article.

Roche Gains CE Label Expansion For Companion Diagnostic To Identify ALK-positive Non-small Cell Lung Cancer Patients

(Yahoo! Finance) July 25, 2017 - Roche today announced that it has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug ZYKADIA (ceritinib).
Read full article.

Powered by OBR Oncology